Breakthrough with 'first Huntington's drug to slow disease'
Development hailed as 'groundbreaking'
Monday, 11th December 2017
Scientists have for the first time fixed a protein defect that causes Huntingdon's disease.
Researchers injected a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.
The success in the early-stage clinical trial has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of US$45 million.
Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability of the drug to tackle the underlying cause of Huntingdon's by lowering levels of a toxic protein was "groundbreaking".
"The key now is to move quickly to a larger trial to test whether IONIS-HTT(Rx) slows disease progression," she said in a statement on Monday.
Huntingdon's is a progressive neurodegenerative disease affecting mental abilities and physical control that normally hits sufferers between the ages of 30 and 50 years before continually worsening over a 10- to 25-year period.
There is currently no effective disease-modifying treatment for the condition, with existing medicines focused only on managing disease symptoms.
Latest
- Young Guyanese pilot Antonio Prittipal fulfills lifelong goa...
-
Trinidad: Grieving mother blames school for son's suicide fo... -
SKN Athletics names world champion Kim Collins as first-ever... -
WINAIR seeks approval to begin flights to Barbuda following... -
Roston Chase, Aaron Jones lead Saint Lucia Kings to lift fir...
Related Articles
Monday, 11th December 2017
Monday, 11th December 2017
Monday, 11th December 2017
Monday, 11th December 2017
Monday, 11th December 2017
Monday, 11th December 2017